Results 71 to 80 of about 28,189 (202)
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis [PDF]
, 2015 Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics.
D'Amico, Roberto +4 more
core +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage. [PDF]
, 2017 BACKGROUND: Injury to cells adjacent to an intracerebral hemorrhage (ICH) is likely mediated at least in part by toxins released from the hematoma that initiate complex and interacting injury cascades.
Chen-Roetling, Jing, Regan, Raymond F.
core +1 more source
Incomplete Wood-Ljungdahl pathway facilitates one-carbon metabolism in organohalide-respiring Dehalococcoides mccartyi. [PDF]
, 2014 The acetyl-CoA "Wood-Ljungdahl" pathway couples the folate-mediated one-carbon (C1) metabolism to either CO2 reduction or acetate oxidation via acetyl-CoA.
Alvarez-Cohen, Lisa +8 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
Neurologijos seminarai, 2019 Multiple sclerosis (MS) is the main cause of acquired neurological disability in the young people. In MS treatment, disease modifying therapies (DMTs) are essential to reduce disease progression by suppressing the inflammatory response responsible for ...
A. Ovčinikova , R. Kizlaitienė
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh +4 more
wiley +1 more source
Personalized Treatment of Patients With Multiple Sclerosis: A Case Report and Literature Review
Medicine Bulletin, EarlyView.ABSTRACT Managing multiple sclerosis (MS) with a highly active disease course presents significant challenges, particularly regarding the timing of therapeutic escalation and the preservation of brain volume. We present a personalized management strategy for a 36‐year‐old male with relapsing‐remitting MS (RRMS) who experienced initial misdiagnosis ...
Fengjun Wang +3 more
wiley +1 more source